Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial

The Lancet Neurology 2026

View at publisher
Authors: Lotte Kjærsgaard, Jonas Wiedemann, Wolfgang Singer, Atsushi Takeda, Anna-Karin Berger, Mimi Folden Flensburg, Lene Hansen, Pekka Kallunki, Kristiina Kompus, Krishan Nighah, Simon Nitschky Schmidt, Mette Nørbæk Jørgensen
+19 more Bodil Svanholm Fogh, Stefano Zanigni, Johan Luthman, Alexandru Barboi, Andres Deik, Cameron Dietiker, Roy Freeman, Deborah Hall, Stuart H Isaacson, Rajeev Kumar, Sheng-Han Kuo, Irene Litvan, Nikolaus McFarland, Patricio A Millar Vernetti, Mara Seier, Takayoshi Shimohata, Valerie Suski, Daniel Truong, Hirohisa Watanabe
DOI: 10.1016/s1474-4422(26)00100-6
Cited by: 5
References: 18

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Genetic Neurodegenerative Diseases Parkinson's Disease and Spinal Disorders

Publication details

Journal / source
The Lancet Neurology
Publisher
Elsevier BV
Volume
25
Issue
6
Pages
560–570
Publication date
24 April 2026
Language
EN